Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × gadobutrol × Clear all
NCT04373564 2026-01-22

ODYSSEY

Guerbet

Phase 4 Recruiting
2,076 enrolled
BreastEndocrineGastrointestinalGenitourinaryNET

Breast Neoplasms, Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT01067976 2014-11-11

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Bayer

Phase 3 Completed
446 enrolled 30 charts
Breast

Breast Neoplasms

NCT01104584 2014-11-11

GEMMA 2

Bayer

Phase 3 Completed
460 enrolled 31 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡